Compare GSK plc (GSK) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Logitech International SA — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while Logitech International SA trades at $98.41 (market cap $14.46B). The key difference: GSK plc is far larger — about 6.4× Logitech International SA's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Logitech International SA for 92 Days on average.
| GSK | LOGI | |
|---|---|---|
Market Cap | $91.88B | $14.46B |
Volume | 7,730,529 | 349,547 |
Sector | Health | Technology |
52-Week High | $61.18 | $126.69 |
52-Week Low | $43.24 | $85.84 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $111.88B | $12.79B |
Dividend Yield | 3.9% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Logitech (LOGI) trades at $98.49, down 3.61% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 16.28% and ROE of 35.29%. Recent news highlights product launches and partnerships, including new headsets and a collaboration with SEGA.
The outlook is balanced, with potential upside to the consensus price target of $107.00, supported by solid fundamentals and innovation. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is divided, with 26.32% buy ratings, reflecting cautious optimism amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
